<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00794690</url>
  </required_header>
  <id_info>
    <org_study_id>CR and the liver</org_study_id>
    <nct_id>NCT00794690</nct_id>
  </id_info>
  <brief_title>Safety Study of Black Cohosh Use by Postmenopausal Women on the Liver</brief_title>
  <acronym>CR-LIVER</acronym>
  <official_title>Influence of Black Cohosh (Cimicifuga Racemosa) Use by Postmenopausal Women on Total Hepatic Perfusion and Liver Functions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Black Cohosh extract is a form of phytoestrogen (estrogen of plant origin) that is effective
      in controlling bothersome hot flushes, while avoiding the dangers of using hormones. Recent
      case reports pointed to potential toxicity of black cohosh on the liver. The investigators
      are trying to verify or refute such allegations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this prospective longitudinal clinical trial is to evaluate changes in total
      hepatic blood flow and liver functions among postmenopausal women using black cohosh
      (cimicifuga racemosa) extract for twelve consecutive months for relief of vasomotor symptoms.

      Prior to using a daily dose of 40 mg of a dry extract preparation of cimicifuga racemosa
      (Klimadynon®) and twelve months after, total hepatic blood flow will be assessed by color
      Doppler ultrasound. Moreover, prothrombin time &amp; concentration, serum albumin, bilirubin,
      gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), alanine aminotransferase (ALT)
      and aspartate aminotransferase (AST) will also be measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on hepatic perfusion and liver functions</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy and tolerability</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>black cohosh extract, liver</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 postmenopausal women</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cimicifuga racemosa extract for the group</intervention_name>
    <description>40 mg of Cimicifuga racemosa extract daily dor 12 months</description>
    <arm_group_label>black cohosh extract, liver</arm_group_label>
    <other_name>Klimadynon®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  an age over 40 years

          -  with a lapse of one year after the last menstruation

          -  symptomatic women without gynecological illness

          -  after naturally occurring menopause

          -  had never used hormonal therapy or had stopped using them for &gt;6 months

          -  accepting to participate after receiving adequate description of the study

          -  accessible for regular follow-up.

        Exclusion Criteria:

          -  vaginal bleeding

          -  active or chronic liver disease and /or abnormal liver functions

          -  present or past thromboembolic disease

          -  present or past neoplasia of the breast or uterus

          -  an endometrial thickness &gt;5 mm by TVS

          -  use of alternative or complementary medicines or herbs for menopausal symptoms within
             the previous three months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMED M NASR, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASSIUT UNIVERSITY, EGYPT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. Obstetrics and Gynecology, Assiut University</name>
      <address>
        <city>Assiut</city>
        <zip>71516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Mahady GB, Low Dog T, Barrett ML, Chavez ML, Gardiner P, Ko R, Marles RJ, Pellicore LS, Giancaspro GI, Sarma DN. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause. 2008 Jul-Aug;15(4 Pt 1):628-38. doi: 10.1097/gme.0b013e31816054bf. Review.</citation>
    <PMID>18340277</PMID>
  </reference>
  <reference>
    <citation>Chow EC, Teo M, Ring JA, Chen JW. Liver failure associated with the use of black cohosh for menopausal symptoms. Med J Aust. 2008 Apr 7;188(7):420-2.</citation>
    <PMID>18393750</PMID>
  </reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2008</study_first_submitted>
  <study_first_submitted_qc>November 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2008</study_first_posted>
  <last_update_submitted>July 31, 2009</last_update_submitted>
  <last_update_submitted_qc>July 31, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Ezat Hamed Sayed</name_title>
    <organization>Department of Obstetrics &amp; Gynecology</organization>
  </responsible_party>
  <keyword>cimicifuga racemosa</keyword>
  <keyword>liver blood flow and functions</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

